Table II.
Amounts injected: | 1 μg |
% entering thymus: | 0.25% |
apmol HEL in thymus: | 0.17 pmol |
Molecules HEL in thymus: | 1011 molecules |
bAssume 10% uptake: | 1010 molecules |
cEfficiency of processing: | 0.1% of uptake |
dNumber of pMHC: | 107 |
eEstimated number of 48-62 complexes/DC: | 25-250 /DC |
*f pMHC/DC | ||||
---|---|---|---|---|
T reg induction | Negative selection | |||
Amts | pMHC/DC | Amts | pMHC/DC | |
3A9 | 1 μg | 25-250 | 5 μg | 125-1250 |
gLB11 | 5 μg | 0.1-1 | 30 μg | 3-30 |
Estimates for the number of pMHC complexes that mediate negative selection versus Treg generation in 3A9 and LB11.3 mice.
The calculation of pmol of HEL per thymus is based on data showing that 0.25% of the injected HEL enters the thymus (Figure 1A).
10% of the injected HEL is taken up by thymic DC and
0.1% of that material is processed to peptide (53).
The number of pMHC complexes generated in the thymus are estimated assuming that
Our estimate of pMHC/DC is based on FACS data showing that 105-106 DC are recovered from a B10.BR thymi and 40% of those DCs are positive for HEL (Table I).
Our estimate of pMHC/DC is based on FACS data showing that 105-106 DC are recovered from a B10.BR thymi and 40% of those DCs are positive for HEL (Table I).
Estimates for LB11.3 assume 250-fold difference in presentation of HEL48-62 versus HEL20-35 based on experimental data (36).
A comparison is shown of the HEL doses that marked the thresholds for negative selection and Treg induction in 3A9 and LB11.3 mice.